MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
4.030
+0.100
+2.54%
Pre Market: 3.994 -0.036 -0.88% 08:09 06/10 EDT
OPEN
3.970
PREV CLOSE
3.930
HIGH
4.140
LOW
3.900
VOLUME
1.41K
TURNOVER
0
52 WEEK HIGH
10.08
52 WEEK LOW
1.660
MARKET CAP
260.73M
P/E (TTM)
-3.4586
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMRX last week (0601-0605)?
Weekly Report · 2d ago
Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained
TipRanks · 06/02 11:37
Immuneering Presents Promising Phase 2a Data For Atebimetinib In Pancreatic Cancer; Shares Drop 22%
NASDAQ · 06/02 09:16
Immuneering Advances Atebimetinib With Positive Phase 2a Results
TipRanks · 06/01 22:49
IMMUNEERING - ANNOUNCES UPDATED PHASE 2A DATA FOR ATEBIMETINIB IN PANCREATIC CANCER - SEC FILING
Reuters · 06/01 20:52
IMMUNEERING - 17.3 MONTH MEDIAN OVERALL SURVIVAL OBSERVED IN 320 MG ITT POPULATION AS OF APRIL 24, 2026 - SEC FILING
Reuters · 06/01 20:52
Analysts’ Top Healthcare Picks: Immuneering (IMRX), Immunocore Holdings (IMCR)
TipRanks · 06/01 18:10
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/01 17:06
More
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.